BB Biotech AG (0JYO)
London Exchange · UK · prices in GBP · close of 22 Oct 2026
Key indicators
| Last close | GBP 49.85 |
|---|---|
| 52-week range | 38.25 – 56.90 |
| Return, 1 month / 3 months | −3.4% / −0.5% |
| Return, 1 year / 3 years | +34.8% / +53.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 47 |
| Volatility (1 year) | 23.2% |
| Worst drawdown (1 year) | -14.6% |
| Average daily value traded | 0.26M GBP |
| Dividend yield | 4.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BB Biotech AG is a Swiss investment company that puts its money into biotechnology businesses. It holds stakes in firms that research and develop medicines and therapies, mainly in Europe and North America. The company is based in Schaffhausen, Switzerland, and its investment work is handled by an external manager. Its shareholders gain exposure to a spread of biotech companies rather than to a single drug developer.
BB Biotech AG trades under the code 0JYO on the London Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
BB Biotech AG (0JYO) trades on the London Exchange in UK. It last closed at GBP 49.85 on 22 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 798 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 34.8% and over the last three months it fell 0.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.2% | ||
| From 52-week high | -12.1% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.5% | ||
| 6-month return | 8.4% | ||
| 12-month return, skipping the last month | 39.6% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.6% | ||
| Liquidity | 39 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.26M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.5% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.7% |
|---|---|
| 1 month | −3.4% |
| 3 months | −0.5% |
| 6 months | +8.4% |
| 1 year | +34.8% |
| 3 years | +53.0% |
| 5 years | −20.8% |
Signals
| 50-day / 200-day average | 52.32 / 47.38 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.10 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Mar 2026 | GBP 2.2500 |
| 21 Mar 2025 | GBP 1.8000 |
| 25 Mar 2024 | GBP 2.0000 |
| 27 Mar 2023 | GBP 2.8500 |
| 21 Mar 2022 | GBP 3.8500 |
| 22 Mar 2021 | GBP 3.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.